An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition

European Journal of Human Genetics

Volumn 21, Issue 12, 2013, Pages 1389-1395

  Ross, Jason ^a   Lockett, Linda ^a   Brookes, Diana ^a   Tabor, Bruce ^a   Duesing, Konsta ^a   Buckley, Michael ^a   Lockett, Trevor ^a   Molloy, Peter ^a   Macrae, Finlay ^b,c   Young, Graeme ^d   Blanco, Ignacio ^e   Capella, Gabriel ^e   Hannan, Garry N ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

cancer; colorectal; COX 2; hereditary; PTGS2; rs5275

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN DERIVATIVE;

ADULT; AGE; ALLELE; ARTICLE; AUSTRALIA; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHROMOSOME 1; CONTROLLED STUDY; DRUG EFFICACY; FAMILIAL CANCER; FEMALE; GENDER; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENOTYPE; HEREDITARY COLORECTAL CANCER; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PTGS2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; YOUNG ADULT;

EID: 84887623503     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.53     Document Type: Article

References (44)

1. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867.
2. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310: 1504-1510.
3. Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-862.
4. Cuzick J, Otto F, Baron JA et al: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507.
5. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
6. Koki AT, Masferrer JL: Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28-35.
7. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM: Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002; 62: 6846-6849.
8. Oshima M, Dinchuk JE, Kargman SL et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
9. Bertagnolli MM, Eagle CJ, Zauber AG et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884.
10. Frattini M, Carnevali I, Signoroni S et al: Cyclooxygenase-2 expression in FAP patients carrying germ line MYH mutations. Cancer Epidemiol Biomarkers Prev 2005; 14: 2049-2052.
11. Papafili A, Hill MR, Brull DJ et al: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-1636.
12. Cok SJ, Morrison AR: The 30-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001; 276: 23179-23185.
13. Moore AE, Young LE, Dixon DA: A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation. Oncogene 2012; 31: 1592-1598.
14. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A: Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138-146.
15. Yang H, Gu J, Lin X et al: Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008; 14: 2236-2244.
16. Jung JH, Chae YS, Moon JH et al: TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 2010; 136: 685-694.
17. Cox DG, Buring J, Hankinson SE, Hunter DJ: A polymorphism in the 30 untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res 2007; 9: R3.
18. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ: Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006; 119: 297-303.
19. Ali IU, Luke BT, Dean M, Greenwald P: Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer 2005; 93: 953-959.
20. Kim JG, Chae YS, Sohn SK et al: Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/ COX2) 8473T4C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 2009; 64: 953-960.
21. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E: Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005; 26: 449-457.
22. Canzian F, Franceschi S, Plummer M et al: Genetic polymorphisms in mediators of inflammation and gastric precancerous lesions. Eur J Cancer Prev 2008; 17: 178-183.
23. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004; 25: 229-235.
24. Hu Z, Miao X, Ma H et al: A common polymorphism in the 30UTR of cyclooxygenase 2/ prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005; 48: 11-17.
25. Park JM, Choi JE, Chae MH et al: Relationship between cyclooxygenase 8473T4C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006; 6: 70.
26. Danforth KN, Hayes RB, Rodriguez C et al: Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 2008; 29: 568-572.
27. Pu X, Lippman SM, Yang H, Lee JJ, Wu X: Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer 2009; 115: 1498-1506.
28. Lurie G, Terry KL, Wilkens LR et al: Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010; 21: 1731-1741.
29. Zhu W, Wei BB, Shan X, Liu P: -765G4C and 8473T4C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 2010; 37: 277-288.
30. Vogel U, Christensen J, Wallin H et al: Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 2008; 639: 89-100.
31. Siezen CL, Tijhuis MJ, Kram NR et al: Protective effect of nonsteroidal antiinflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogen Genomics 2006; 16: 43-50.
32. Saunders IW, Ross J, Macrae F et al: Evidence of linkage to chromosomes 10p15.3-p15.1, 14q24.3-q31.1 and 9q33.3-q34.3 in non-syndromic colorectal cancer families. Eur J Hum Genet 2012; 20: 91-96.
33. Lange C, Laird NM: On a general class of conditional tests for family-based association studies in genetics: the asymptotic distribution, the conditional power, and optimality considerations. Genet Epidemiol 2002; 23: 165-180.
34. Van Steen K, Lange C: PBAT: a comprehensive software package for genome-wide association analysis of complex family-based studies. Hum Genomics 2005; 2: 67-69.
35. Horvath S, Xu X, Laird NM: The family based association test method: strategies for studying general genotype-phenotype associations. Eur J Hum Genet 2001; 9: 301-306.
36. Chen WM, Manichaikul A, Rich SS: A generalized family-based association test for dichotomous traits. Am J Hum Genet 2009; 85: 364-376.
37. Mann JR, DuBois RN: Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004; 10: 145-152.
38. Lange C, Blacker D, Laird NM: Family-based association tests for survival and timesto- onset analysis. Stat Med 2004; 23: 179-189.
39. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A: Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 1998; 51: 1271-1276.
40. Koo JH, Jalaludin B, Wong SKC, Kneebone A, Connor SJ, Leong RWL: Improved survival in young women with colorectal cancer. Am J Gastroenterol 2008; 103: 1488-1495.
41. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al: Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991-1004.
42. Campbell-Thompson M, Lynch IJ, Bhardwaj B: Expression of estrogen receptor (ER) subtypes and ERb isoforms in colon cancer. Cancer Res 2001; 61: 632-640.
43. Konstantinopoulos PA, Kominea A, Vandoros G et al: Oestrogen receptor beta (ERb) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39: 1251-1258.
44. Szczeklik W, Sanak M, Szczeklik A: Functional effects and gender association of COX-2 gene polymorphism G(-765)C in bronchial asthma. J Allergy Clin Immunol 2004; 114: 248-253.